Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An International, Phase 3, Multicenter, Randomized, Open- Label Trial Comparing Balixafortide in Combination With Eribulin Versus Eribulin Alone in Patients With HER2 Negative, Locally Recurrent or Metastatic Breast Cancer

Trial Profile

An International, Phase 3, Multicenter, Randomized, Open- Label Trial Comparing Balixafortide in Combination With Eribulin Versus Eribulin Alone in Patients With HER2 Negative, Locally Recurrent or Metastatic Breast Cancer

Not yet recruiting
Phase of Trial: Phase III

Latest Information Update: 02 Jan 2019

At a glance

  • Drugs Balixafortide (Primary) ; Eribulin
  • Indications Advanced breast cancer
  • Focus Registrational; Therapeutic Use
  • Sponsors Polyphor
  • Most Recent Events

    • 20 Dec 2018 Status changed from planning to not yet recruiting.
    • 20 Dec 2018 Planned initiation date changed from 1 Jan 2019 to 1 Mar 2019.
    • 03 Dec 2018 According to a Polyphor media release, the company announced that FDA has agreed with the proposed indication for this treatment and confirmed the possibility to submit a filing for accelerated approval at the end of the recruitment on the basis of the analysis of the overall response rate (ORR), confirmed by an independent blinded review, and of the associated durability of response.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top